← Therapy pipeline
Investigational · Obesity development

BI 3034701

BI3034701 · Boehringer Ingelheim / Gubra

An investigational triple receptor agonist targeting GLP-1, GIP and NPY2 receptors.

GLP-1GIPNPY2
Obesity stagePhase 2Updated as of November 2026
SponsorBoehringer Ingelheim / Gubra
TargetsGLP-1 + GIP + NPY2
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylin—
OTHOther targetsTargeted
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Injection
Phase 2Phase 2 dose-finding study initiated July 2026
Milestone → next

Latest: Boehringer Ingelheim initiated a Phase 2 obesity study in July 2026; Gubra originated the candidate.

Next: Dose-finding study results; no readout timing is posted.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies1 record

Phase 2

NCT07662122 · Phase 2 dose finding

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Subcutaneous dose-finding study in adults living with overweight or obesity; the study is designed to assess efficacy and safety.